Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting
Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting
—Data Presented at the CHEST 2024 Annual Meeting—
—在2024年CHESt年会上呈现的数据—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found HERE. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.
新泽西州布里奇沃特，2024年10月8日 / PRNewswire / - 全球生物制药公司Insmed Incorporated（纳斯达克：INSM）今天在非囊性纤维化支气管扩张症患者中评估布伦索卡替治疗的全球性、随机化、双盲、安慰剂对照的III期ASPEN研究中，推出正面的突破性分组数据。 这些分组分析的详细信息海报可以在此处找到。 这些数据于10月6日至9日在波士顿举行的CHESt 2024年年会上进行展示，与Insmed呼吸学产品组合中的其他多个演讲一起。
